hodgkin lymphoma | Hodgkin lymphomas

Hodgkin lymphomas

Hodgkin's lymphoma often affects young patients (25-30 years), and is frequently manifested by lymph nodes in the neck, sweats, itching.

There is a second type of incidence after 60 years.

It is one of the few lymphomas treated by the association chemotherapy + radiotherapy.

Large-cell diffuse lymphoma B
Large B-cell diffuse lymphoma (LDGC-B) is the most common lymphoma, accounting for about 40% of all lymphomas.

The disease is often in the form of poly-adenopathies (several lymph nodes) but can also be achieved by one or more organs.

LYSA Studies open to inclusions
First line
Entospletibin phase Ib-II Ento-RCHOPEtude in patients with large B-cell diffuse lymphoma newly diagnosed with aaIPI ≥ 1 treated with R-CHOP
Phase I-II
IPI > 1
60-80 years
Phase III POLARIXEtude comparing R-CHOP standard to R-Polatuzumab CHP in patients with large B-cell diffuse lymphoma in the 1st line
Phase III
IPI > 1
18-80 years
Relapse or refractory
Selinexor phase Ib SELINDAEtude in patients with large B-cell diffuse lymphoma treated with RGDP
Phase Ib
Eligible Autograft
Multicentre phase II PIVEREtude, open, with treatment arm, evaluating pixantrone in patients treated with rituximab, ifosfamide, and etoposide having non-Hodgkin's lymphoma B aggressive CD20 positive, refractory or relapse
Phase II
Eligible and ineligible autografting
Phase II GATAEtude Evaluating the Atezolizumab combination, with Venetoclax and Obinutuzumab in patients with relapsing lymphoma or refractory
Phase II
Eligible Autograft
NIVEAUEtude Comparing treatment with (R)-GemOx (rituximab-gemcitabine oxaliplatin), whether or not associated with Nivolumab in patients with aggressive non-Hodgkin's lymphoma at first relapse or primary refractory, not eligible for transplant Haematopoietic
Phase III
Ineligible Autograft
LYSA studies soon open to inclusions
Real-time molecular RT3Caractérisation of diffuse large cell lymphoma B


LYSA studies whose inclusions are suspended
Tazemetostat (EPZ-6438) phase Ib-II EPI-RCHOPEtude in patients with R-CHOP-treated high-risk large B-cell lymphoma
Phase I-II
IPI > 2
60-80 years

Follicular lymphomas
Follicular lymphoma is one of the indolent lymphomas, and represents the 2nd subtype of frequency lymphoma.

His clinical evolution is slow. Sometimes it turns into an aggressive subtype of lymphoma (it is then mostly diffuse lymphoma with large B cells).

LYSA Studies open to inclusions
First line
Randomized phase III FLIRTEtude evaluating two routes of administration (IV vs SC) of rituximab in patients with low-mass follicular lymphoma in 1st line


Relapse or refractory
Phase II GATAEtude Evaluating the Atezolizumab combination, with Venetoclax and Obinutuzumab in patients with relapsing lymphoma or refractory
Phase II
Ineligible Autograft
Selinexor phase Ib SELINDAEtude in patients with large cell B lymphoma treated with RGDP
Phase Ib
Eligible Autograft


LYSA Studies (1st line) whose inclusions are suspended
R2-CHOP
ProtocolHodgkin lymphomas
Hodgkin's lymphoma often affects young patients (25-30 years), and is frequently manifested by lymph nodes in the neck, sweats, itching.

There is a second type of incidence after 60 years.

It is one of the few lymphomas treated by the association chemotherapy + radiotherapy.Mantle cell lymphomas
The lymphoma of the mantle is a rarer lymphoma, appearing around 55 years.

Several areas of the body, including the digestive tract, are reached at the time of diagnosis.

LYSA Studies open to recruitment
First line
MCL R2 elderlyEfficacité and tolerance of R-Chop + R-HAD versus R-Chop induction Immunochimiothérapie treatment alone, followed by maintenance treatment with Lenalidomide + rituximab versus rituximab alone in elderly patients with Mantle lymphoma


Relapse or refractory
Selinexor phase Ib SELINDAEtude in patients with large B-cell diffuse lymphoma treated with RGDP
Phase Ib
Eligible AutograftOther indolent lymphomas
Indolent lymphomas derive from memory B lymphocytes, and include the lymphomas of the marginal zone, the lymphomas of lymphoid tissues associated with the mucous membranes (MALT) and the boundary entities.

LYSA Studies open to recruitment
Phase II GATAEtude Evaluating the Atezolizumab combination, with Venetoclax and Obinutuzumab in patients with relapsing lymphoma or refractory
Phase II
Non-MALT